BULLISH Technical Breakout alert : BIEL

http://www.straightstocks.com/stock-watch/bullish-technical-breakout-alerts-nasdaqncoc-otcbiel-pk/

First off..I love the Bull picture. Read the article above. It has lot of good info. Here is the best part that I liked :

The dermal patch delivery system creates a multitude of new product opportunities for chronic and acute inflammatory conditions. The market potential is estimated at $10 billion or 400 million incidents worldwide. The distinctive value proposition of ActiPatch is the delivery of drug-free therapy that reduces pain and inflammation and accelerates healing by 30% to 50% when compared with the present standard methods of patient care. The current major applications are:

• Medical Surgeries
• Chronic Wounds
• Oral Surgeries
• Sprains and Strains
• Lower Back Pain
• Chronic Repetitive Stress Injuries, Heel Pain, Carpal Tunnel, Bursitis, etc.

Below is a list of the Company’s accomplishments to date.

• United States Food and Drug Administration market clearance
• Canadian market approval for relief of pain in muscosketal complaints in both medical and over-the-counter markets
• CE Mark (European Common Market) Certification for the medical and retail over-the-counter markets
• ISO Certification
• Chosen as “One of 9 Medical Breakthroughs That May Change Your Life” by MedicalHeadway.com
• 15+ domestic independent sales agents
• 20+ International distributors with additional agreements in place or awaiting regulatory approvals
• A medical research agreement with the David Genecov, MD, Dallas Medical Center, a leading medical researcher to supervise and write manuscripts for four studies, plantar fascitis (heel pain), ankle sprains, breast augmentations, and cesarean sections.
• Canadian retail product line launched in June of 2008, actively interviewing distribution partners throughout the rest of the world.
• A solid intellectual property portfolio covering both the product design and the pulse signature.
• A 3-year pipeline of new products for treatment of sports injuries, bone fractures, chronic injuries, chronic wounds, skin conditions, arthritis and post-operative care.
• Product now available online to the consumer market via multiple websites in several countries.
• Projected annual sales in 2008 of over $2,000,000.

Biomedreports article on BIEL (very positive)

Any serious BIEL investor should take some time and read this entire article by Biomedreports.

http://biomedreports.com/articles/most-popular/17424-banking-on-biels-upcoming-study-results-against-tylenol.html

Few Excerpts from the article :

“We found newspaper articles dating back over twenty years in which scientists urged stronger warning labels on every bottle of acetaminophen, based on evidence that countless Americans unwittingly took toxic doses that harmed their livers“

“That push and the results of a soon to be released study by Bioelectronics Corp. (OTC:BIEL) set the table for an intriguing penny play in the coming days. The company made this year’s 10 Stock BioMed Momentum Index, with investors riding the wave of excitement about the technology and pending FDA decisions, but the upcoming news flash will likely make shares of the micro-cap company run up once again. “

“Company officials won’t yet officially disclose what the study results will reveal, but there are strong hints in what was released as part of the pilot section of the study last month. That Institutional Review Board (IRB) supervised study is directed at comparing the effects of the company’s ActiPatch® Therapy to acetaminophen in the form of Extra Strength Tylenol® for the treatment of delayed onset muscle soreness (DOMS). “

 

NYC Cocktail Party by Joe Noel and Simon : UPDATE

Contributor : pbar673874

I did go to the event tonight in NYC, and it honestly wasn’t that special. Below are the highlights of what I heard:

• Joe said that the dilution was necessary in order for them to pay off the “toxic debt,” but they now have enough cash he thinks. They are currently completing the audit, and once this is done we should get a good idea of the cash position. He doesn’t think further dilution is necessary at this point.

• The commericals have been completed, and Joe says they are pretty good. Once they find out about the FDA approval, the commericals will be aired ASAP.

• For sales, Joe thinks that the best thing for them at this point is to do infomercial sales. Besides that, they think it’s going to do well in the stores. The international sales have also been good.

• The million dollar question is approval, and they still don’t know when it is going to arrive. The one thing he did say is that actipatch should be approved before allay. They don’t see any problems or risks of approval w/ the allay approval, but the FDA is asking more questions due to the application location. Joe doesn’t agree w/ this since it is approved for the eye. Even tho the approval can come at ANY moment, they are guessing it will be a couple more weeks.

• Joe says that he can sell his shares at any moment, but he still has them and more $$ invested in the company. He said that he has been w/ them from the start and has helped fund them when they ran out of cash. Joe definitely gets a bad rap, but he truly does seem to believe in biel and the future success of the company.

• Biel wants to get off the pink sheets, and they are hoping to get this done over the next few weeks. One of the ways that Joe said this could be done is by finding a dead company on the BB that is still there and spin off w/ them. I have seen this before with IVOB.OB. They are a fertility company that was formely a salsa company. There was another way that I can’t think of at the moment. Biel wants to be viewed as a legit company, and this is why they are having the audit happen so they can quiet the bashers. This audit will shut everyone up and prove they are a legit company.

• Even tho I don’t believe him, Simon thinks that biel is going to eventually get bought out for $1 even with the o/s being 1.5billion. I think this is rather agressive and unrealistic.

• Both Joe and Simon are annoyed about the bleeding of the stock, but they said there was been a ton of shorting whihc was scrwed biel over. Overall they say were going to be fine.

Overall it really wasn’t a big showing, but it was rather nice to finally meet Joe. For all the crap he takes on the MB’s, he does seem like a really nice guy. I did enjoy making fun of him about how ever since PR he puts out turns the stock from green to red. The one thing he did tell me that is if people do have questions, just call him or andrew. Sorry if this is not what you were expecting, but there were other people jumping in while we were talking, so not everything was answered fully.

This is just what I remeber do please don’t go buying/selling based on this summary. Just so it’s all out on the table, i’m long 260K shares.

————————————————————————

Contributor: videoai/Jo

Hi this is Jo from NYC.
I met Joe Noel, Simon & other investors. I was only one didn’t wear black suit with tie ^ ^.There was no official announcement at the meeting. 20-30 suits & me were standing in a hall, drinking while chatting about BIEL. And I had a chance to talk to Joe for an hour.

Asked some questions to JOE and SIMON.

1. Why did Google show (NDA) after name of Bioelectronics Corp last 2 weeks? What does 3M company to do with BIEL?
Joe - ‘No idea. Maybe New Drug Applications.’ (seems he doesn’t want to tell me anything.)

2. After clearing FDA, when Allay patch will be available in USA?
Joe - ‘Allay patches are already shipped in here. Just waiting for the time comes.’

3. In September Biel submitted 510K. What was the ‘Multiple applications of Actipatch ‘ about?
Joe - ‘It was 5 body parts of Muscular pain patch applications in one.’
Means, one ActiPatch 510K clearance will allow to sell 5 products in USA.

4. What is story with Audit?
Joe – ‘Simply BIEL wants to move bigger market; OTCBB. In 2 weeks the result of Audit will come out in public.’

5. After Audit do you need SEC first to move to OTCBB? Usually does it take two months for SEC, right?
Joe - ‘Not necessary need to file SEC to jump to OTCBB. There is other way as well.’ (not clear what he said after this. Seems like after the Audit result, BIEL will rush to move up. ^ ^)

6. Since ActiPatch was received FDA Clearance before, this FDA application result might come out earlier than usual? Some people in Yahoo BM said so.
Joe - That’s not right. Have to wait same as other applications; FDA 510K CLASS III! (He mentioned only class III, not Class II at all.)

7. When does Tylenol Study out?
Joe - ‘result out, announce soon’.

8. Depends on study result, there is any possibility Tylenol company (J&J?) might sue BIEL?
Joe - We have a study result. They can not sue us.

Question to Simon —
*What to to with Goldman Sachs with BIEL?
Simon – ‘They are one of majority share holder of BIEL.’

This is what I can say about the BEER meeting – I drank beers only ^ ^. I didn’t find Sully or other families names over there. Everyone wore black suit and had no name tag on it.

I felt, BIEL is a time to move up!

JO

SeekingAlpha article on BIEL

Mike Rabe’s original article link : http://seekingalpha.com/article/170458-3-holiday-stocking-stuffers-for-big-gains-in-2010

Makes inexpensive, disposable drug-free anti-inflammatory devices. For penny players, Bioelectronics provides one of the best risk/ reward ratios out there. BIEL is an extreme trade (it currently trades for around 7 cents per share).

Bioelectronics is currently an FDA play. Bioelectronics CEO, Andrew Whelan, had told me in an email this week that the Company is expecting to hear back from the FDA any day now on its application for 510(k) clearance to market its Allay Menstrual Pain Relief Patch product and OTC clearance for its ActiPatch Therapy products.

Bioelectronics is also expected to announce in November statistically significant study results that compared the effects of its ActiPatch® Therapy product to acetaminophen in the form of Extra Strength Tylenol® for the treatment of delayed onset muscle soreness (DOMS).

With three of its five FDA filings completed, Bioelectronics is now focusing on revenue generation. Bioelectronics has made no secret in the fact that it hopes to be acquired by a large industry player down the road.

These three stocks present an outstanding chance to not only beat the Street in 2010, but to beat it soundly. But like all holiday shopping deals, these discount sale prices will not last much longer.

Awesome article on Adam Feuerstein (ADAM WHO ???)

http://biomedreports.com/articles/most-popular/11704-opinion-qadam-whoq.html

Few excerpts :

“What’s with the engrossing level two interest in the trading action, anyway? Perhaps that’s one reason, among others, that investigative bodies like FINRA have taken an interest in his penmanship?”

“I’ll never forget sitting behind Mr. Feuerstein at the recent Rodman & Renshaw conference and watching him and a sidekick intensely monitoring Level 2 trading on a laptop before attacking one of the presenters behind the podium during the time allotted for investors (not media members with their own agenda) to ask questions.”

“Adam still has no clue what the science behind BioElectronics is about or why companies like Kimberly Clark have taken an interest in what he describes as “magnets embedded in a bandage to reduce pain and swelling.”

“Disclosure: LONG on just about everything Adam suddenly bashes”

Reuters upgrades BIEL to OUTPERFORM (Pdf link)

In my opinion this is huge news. An analyst at Reuters covering BIEL means we are getting the exposure that we need.

Certainly lends lot of credibility to the company and its products.

http://www.sharefile.org/showfile-2034/file.pdf

BIEL Overview (but in great detail)

Contributor: bms3232 (via 2cow.net)

BioElectronics Corporation develops and markets drug-free anti-inflammatory patches. The company’s products include ActiPatch Therapy, a dermal drug-free, painless, and pulsed energy patch with an embedded battery operated microchip that delivers pulsed electromagnetic frequency therapies to accelerate healing of soft tissue injuries. Its technology provides pulsed electromagnetic energy therapy that is used to reduce swelling, relieve pain, and enhance the healing of post-surgical incisions, chronic wounds, and orthopedic conditions. The company markets its products in the United States, Canada, and Europe. BioElectronics Corporation sells its products to wholesale distributors, as well as directly to hospitals and clinics. Recent Highlights

• BioElectronics has retained industry leader, Schulberg MediaWorks as its marketing partner. Work on the DRTV spots has already begun with initial airing expected within 60 days. Initially, the Canadian and selected other English speaking markets will be targeted, but the U.S. market will also be heavily targeted once FDA clearance is received.

• Indendent analyst Carrie Snyder, places a target price on BIEL shares of between $0.30 and $0.50, should expected FDA clearances be granted.

• Clinical Results — David G. Genecov, M.D. FACS FAAP, provided preliminary data on a heel and foot pain study showing strong efficacy and 100% safety using the ActiPatch device. The study also showed study participants were able to significantly reduce their use of acetaminophen, the active ingredient in Tylenol, and non-steroidal anti-inflammatory drugs (NSAIDs). Considering the recent FDA panel recommendation relating to acetaminophen usage, these results are highly significant.

• Clinical Studies and FDA Filings — Clinical studies in the areas of breast augmentation, Cesarean section, Uveitis, and several areas of surgical recovery are quickly coming to a close with data expected over the coming months. With the data provided by the Genecov study, the management team plans to accelerate its FDA 510(k) pre-marketing clearance filing for general musculoskeletal complaints designed to lead to over-the-counter approval. In addition, the Company will soon submit an additional application of 510(k) pre-marketing clearance for general surgical recovery.

• International Distribution Expansion — International distribution relationships continue to advance at a rapid rate. The Company announced it will soon be entering the German and Spanish markets, which will augment other international markets, particularly the Italian, Korean and Canadian markets, which are already showing revenue acceleration. Several Asian distribution partnership agreements are currently being negotiated.

• Financials — Management indicated that the financial position of the Company has improved dramatically over the past few months. Further payments have been made on convertible debentures with balances dropping from more than $910,000 one year ago to less than $50,000 today. Elimination of all convertible debenture balances is likely over the coming weeks. BioElectronics is maintaining very strong gross margins and tight expense controls, resulting in the Company operating at near breakeven levels. The working capital position at the Company has also significantly improved. The recent U.S. Government Export-Import Bank guarantee is expected to further improve the working capital position.

• Company Priorities — The priorities for BioElectronics remain the completion of clinical trials, FDA submissions, expansion of international distribution, and the further development of our patented, drug-free brands: Allay, ActiPatch and RecoveryRx.

• BioElectronics Receives Groundbreaking Patent – PEMF technology has been proven safe and effective in hundreds of peer-reviewed scientific studies. Up until now, however, PEMF devices have been very expensive large devices and usually based in clinical settings such as clinics or hospitals. Through the use of advanced micro-circuitry the engineers at BioElectronics have shrunk this technology into a wafer-thin device that can be worn directly on the skin to relieve pain, swelling and speed healing.

Why this is a hot stock

-Biel is waiting on FDA approval for its Allay Patch anticipated 2nd half of August while planning on filing 2 more FDA 510k submissions. Per last conference call on July 28th, 2009 , 2 institutional investors have invested in Biel which is very rare and a real honor for companies traded on the Pink Sheets.

- Wednesday September 30, 2009 BioElectronics Corp. announced the availability of a new product targeted at the $10 billion dollar veterinary care market, the HealFast Therapy PetPatch(TM).

- Monday October 19, 2009 BioElectronics Corp. announced the initial results from the pilot section of its ongoing acetaminophen comparison study. The study, which is expected to be complete during early November, compares the effects of ActiPatch? Therapy to acetaminophen in the form of Extra Strength Tylenol? for the treatment of delayed onset muscle soreness (DOMS).

Delays could be a HUGE blessing (think IRS)

Contributed by : briguytc2005

Hey,

I read this on another board, and wanted to sum it up and give my opinion about it…

For those of you/us who are truly long on this; these delays could end up being very beneficial.

Although the PPS keeps dropping, if you are truly long you can add to your position, average down, or just hold. (Its not a loss until you sell it) The other portion of the delay that can be beneficial is TAXES! Many on this board have been here since 1-2 cent range and even less… However, if those were going to sell today (although a nice profit is at hand) taxes could be onwards of 40% of your gains!

The sentiment across the board is that this is a great product and it will be approved. If this is the case, every day is one step closer to approval and one day closer to not paying short-term capital gains. If you’re truly a long, PPS on approval shouldn’t even matter… its all about the revenue produced from the sales of this product! YES, approval is a nice flip if you land the buying and selling right, but holding a company that has approval usually pays out much more in the long run.

Sorry this is a bit long winded, but be optimistic!

Hope everyone is doing well, and good luck!

CBS, FOX, NBC News Coverage links

It is nothing short of HILARIOUS that if we dig up information about the company which is real and helpful for investors, we are called pumpers. If you are a long investor, you bought in for the products and innovation not PPS. The products and innovation is what drives the PPS. It is just a by-product. These videos have been posted before. But I would like to post some more links :

NBC News
http://www.youtube.com/watch?v=P6vmg1MfP…

FOX 4 News
http://www.youtube.com/watch?v=Lf6Xjsj40…

CBS (Scroll to 2:23 seconds to see Actipatch)
http://www.youtube.com/watch?v=uW6WkU_TP…

Pet Patch
http://www.youtube.com/watch?v=4Mj2r5C-m…

Dr. Whiteman’s view on Plastic Surgery application
http://www.youtube.com/watch?v=TuqbumvXS…

Official BIEL Video :
http://www.youtube.com/watch?v=L-noqaD2S…

Josey’s call with Andrew Whelan (BIEL CEO)

Contributed by: joseytheoutlawwales

Hey to those folks interested.

I spoke with Mr. Whelan for about 20 minutes yesterday, not actually about FDA or investor sentiment or O/S, but rather the medical implications of their current push against the Tylenol brand.

I did disclose that I am a BIEL investor, and in truth i just picked up another 25000 today at 0.067.

Now you can believe I spoke with him or not, I truly do not care. However, for those who are actually LONG investors of BIEL, please take a moment to smile and feel confident.

He said that in their clinical trial they absolutely crushed Tylenol (using a VAS, or Visual Analog Scale for rating pain relief, which is standard for this type of subjective clinical study).
Data was: 32 for the control group, 31 for Tylenol, 1.78 for Actipatch.

CRUSHED tylenol. Those were his words.

I’m not telling you to rush out and buy buy buy. Continue your own DD.

In all truthfullness, I for one actually debated after my phone conversation to liquidate every single stock I own to dump the motherload into BIEL today. Seriously.

But I still had to remind myself of this still being just a pink sheet stock, and not doing something quite that foolish.

Holding 230000 now, which is small fries compared to some, but about what I can stomach the potential down ride prior to approval.

I hope we hold the current levels prior to approval. but even if we dip, remain confident.

Andy’s parting words were, “we kind of finally feel as a company as if we’re at the end of the hockey stick, about to absolutely fly.”

just fyi, do with it as you will.